SYK - Stryker Corporation

NYSE - NYSE Delayed Price. Currency in USD
175.10
+5.69 (+3.36%)
At close: 4:02PM EDT

175.00 -0.10 (-0.06%)
Pre-Market: 8:31AM EDT

Stock chart is not supported by your current browser
Previous Close169.41
Open171.16
Bid171.30 x 800
Ask177.93 x 800
Day's Range171.12 - 175.50
52 Week Range146.80 - 179.84
Volume1,359,714
Avg. Volume1,222,906
Market Cap65.486B
Beta (3Y Monthly)0.26
PE Ratio (TTM)61.83
EPS (TTM)2.83
Earnings DateOct 25, 2018
Forward Dividend & Yield1.88 (1.10%)
Ex-Dividend Date2018-09-27
1y Target Est187.27
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    MERGER ALERT – EGN, KTWO and RLJE: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies

    NEW YORK, Oct. 15, 2018 -- The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on.

  • GlobeNewswire2 days ago

    Analysis: Positioning to Benefit within PTC, H&R Block, GenMark Diagnostics, American International Group, Newmont Mining, and Stryker — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Oct. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Investopedia7 days ago

    Top 3 Healthcare Stocks for 2018

    The healthcare industry is watching the Trump presidency closely. President Trump's promise to repeal and replace Obamacare hit repeated stumbling blocks in Congress. Despite the uncertainty surrounding these efforts to overhaul the nation's healthcare system, a number of healthcare stocks rose dramatically throughout 2017.

  • How Intuitive’s Bottom Line Is Expected to Look in Q3 2018
    Market Realist7 days ago

    How Intuitive’s Bottom Line Is Expected to Look in Q3 2018

    Intuitive Surgical’s (ISRG) cost of goods sold is expected to rise 16.82% from $227.5 million in the third quarter of 2017 to $265.76 million in the third quarter of 2018. In the third quarter, Intuitive Surgical is expected to incur selling, general, and administrative expenses of $207.11 million compared to $204.8 million in the third quarter of 2017, reflecting a potential increase of 1.13%. Intuitive Surgical is expected to report net income of $258.28 million in the third quarter compared to net income of $297.5 million in the third quarter of 2017, indicating a contraction of 13.18% in the company’s net margins.

  • Why Most Analysts Are Bullish on Intuitive Surgical in October
    Market Realist7 days ago

    Why Most Analysts Are Bullish on Intuitive Surgical in October

    Eleven of the 18 analysts covering Intuitive Surgical (ISRG) in October have given the stock “buy” or higher ratings. Six analysts have given it “hold” ratings, and one has given it a “sell” rating.

  • General Dynamics' Unit Wins Arms Deal for Stryker Vehicles
    Zacks8 days ago

    General Dynamics' Unit Wins Arms Deal for Stryker Vehicles

    General Dynamics' (GD) Stryker Family of armored combat vehicles provides the U.S. Army with an effective mix of capabilities, including infantry transport, offensive firepower and reconnaissance

  • General Dynamics Wins $367M Army Deal for Upgrading Stryker
    Zacks9 days ago

    General Dynamics Wins $367M Army Deal for Upgrading Stryker

    General Dynamics' (GD) Stryker Land Vehicle assists the U.S. Army with capabilities that include infantry transport, offensive firepower and reconnaissance.

  • GlobeNewswire13 days ago

    Stryker to host analyst meeting

    A simultaneous webcast and replay of the Company`s presentation will be available on Stryker`s website at www.stryker.com. To listen to the meeting via phone dial (844) 826-0610 (domestic) or (973) 453-3249 (international) and be prepared to provide conference ID number 6393206 to the operator. To hear this recording, you may dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and enter conference ID number 6393206.

  • Stryker's HyperBranch Buyout to Boost Neurotechnology Business
    Zacks14 days ago

    Stryker's HyperBranch Buyout to Boost Neurotechnology Business

    Stryker's (SYK) craniomaxillofacial division's market prospects bright.

  • The Wall Street Journal16 days ago

    [$$] Stryker Buys HyperBranch for $220 Million

    Stryker Corp. on Monday said it acquired venture-backed medical-device maker HyperBranch Medical Technology Inc. in an all-cash deal valued at about $220 million.

  • GlobeNewswire16 days ago

    Stryker acquires HyperBranch Medical Technology, Inc.

    October 1, 2018 - Stryker (SYK) announced today the acquisition of privately-held HyperBranch Medical Technology, Inc. for a total equity value of approximately $220 million in an all cash transaction. HyperBranch is dedicated to developing medical devices based on its proprietary polymers and cross-linked hydrogels. "The acquisition of HyperBranch supports our growth strategy within our Neurotechnology business," said Spencer S. Stiles, Group President, Neurotechnology, Instruments and Spine for Stryker.

  • What ResMed’s Valuation Trend Indicates
    Market Realist19 days ago

    What ResMed’s Valuation Trend Indicates

    Ten analysts covered ResMed (RMD) in September. Four analysts gave ResMed stock a “buy” or higher rating, five analysts gave it a “hold” rating, and one analyst gave it a “strong sell” rating. The mean rating for ResMed stock is 2.6, and its target price is $104.69.

  • MarketWatch19 days ago

    Stryker to pay $7.8 million fine to SEC for FCPA violations

    Stryker was fined $7.8 million by the Securities and Exchange Commission for what the agency said was the second Foreign Corrupt Practices Act action against the medical devices company. According to the SEC, Stryker's internal accounting controls were not sufficient to detect the risk of improper payments in sales of products in India, China, and Kuwait, and Stryker's India subsidiary failed to maintain complete and accurate books and records. As part of the SEC sanction, Stryker, which neither admitted nor denied the finding, must now retain an independent compliance consultant to review and evaluate its internal controls, record-keeping, and anti-corruption policies and procedures. In 2013, Styker also settled FCPA violations.

  • Reuters19 days ago

    Stryker to pay $7.8 mln to settle Foreign Corrupt Practices Act charges

    Medical device company Stryker Corp. will pay $7.8 million to settle charges it violated the Foreign Corrupt Practices Act, without admitting or denying the allegations, the top U.S. securities regulator ...

  • What’s the Upside Potential for Agilent Technologies Stock?
    Market Realist19 days ago

    What’s the Upside Potential for Agilent Technologies Stock?

    In the last three months, Agilent Technologies (A) stock has risen from $61.14 on June 27, 2018, to $70.33 in September 2018. The enterprise value of Agilent is $22.11 billion, and its enterprise-value-to-revenue ratio is 4.6x. Its current ratio, a metric of how effectively a company can meet its short-term obligations, stands at 3.6x.

  • Agilent’s Top Line Expected to Stay on Upward Trajectory
    Market Realist20 days ago

    Agilent’s Top Line Expected to Stay on Upward Trajectory

    Agilent Technologies (A) generated total revenues of $1.2 billion in the third quarter of 2018 compared to $1.11 billion in the third quarter of 2017. Agilent generates revenues from product sales and services. For fiscal 2018 and 2019, Agilent is expected to generate revenues of $4.88 billion and $5.18 billion, respectively, compared to $4.47 billion in fiscal 2017.

  • What Waters Corporation’s Valuation Trend Indicates
    Market Realist20 days ago

    What Waters Corporation’s Valuation Trend Indicates

    The mean rating for Waters Corporation stock is 2.8, and its target price is $205.79, implying an upside potential of 5.7% over its closing price of $194.69 on September 26. In comparison, for peers Danaher (DHR), Stryker (SYK), and Thermo Fisher Scientific (TMO), analysts have mean ratings of 1.83, 1.93, and 1.63, respectively, and target prices of $114.07, $184.43, and $252.86, respectively. From its level of $218.70 on January 29, the stock corrected to $186.44 on August 15.

  • How Waters Corporation Is Positioned in 2018
    Market Realist20 days ago

    How Waters Corporation Is Positioned in 2018

    Waters Corporation (WAT) is a specialty measurement company and a pioneer in analytical workflow solutions that involve liquid chromatography, mass spectrometry, and thermal analysis innovations. Additionally, Waters Corporation’s thermal analysis, rheometry, and calorimetry instruments are used in predicting the stability and suitability of fine chemicals, pharmaceuticals, water, polymers, and viscous liquids. Waters Corporation generated total revenue of $596.22 million in the second quarter compared to $558.25 million in the comparable period of 2017.

  • GlobeNewswire26 days ago

    MERGER ALERT – IVTY, EGL and ESND: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies

    NEW YORK, Sept. 21, 2018-- The following statement is being issued by Levi & Korsinsky, LLP:. Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following ...

  • GlobeNewswire27 days ago

    Stryker to host conference call on October 25, 2018

    September 20, 2018 - Stryker (SYK) announced that it will host a conference call on Thursday, October 25, 2018 at 4:30 p.m., Eastern Time, to discuss the Company`s operating results for the quarter ended September 30, 2018 and provide an operational update. To participate in the conference call dial (844) 826-0610 (domestic) or (973) 453-3249 (international) and be prepared to provide conference ID number 9086309 to the operator. To hear this recording, you may dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and enter conference ID number 9086309.

  • What’s the Upside Potential of Thermo Fisher Scientific Stock?
    Market Realist28 days ago

    What’s the Upside Potential of Thermo Fisher Scientific Stock?

    So far in 2018, Thermo Fisher Scientific (TMO) stock has generated double-digit returns for investors. Boosted by its strong financial performance, it’s risen from $192.98 on January 2 to its current level of $240 in September.

  • What Thermo Fisher Scientific’s Gross Margin Trend Indicates
    Market Realist28 days ago

    What Thermo Fisher Scientific’s Gross Margin Trend Indicates

    Thermo Fisher Scientific (TMO) is a leading provider of analytical instruments, equipment, reagents, and consumables. Thermo Fisher Scientific generated total revenue of $6.08 billion in the second quarter compared to $4.99 billion in the comparable period of 2017. Thermo Fisher generates revenue from product sales and services.

  • Investopedialast month

    Top 3 Healthcare Stocks for 2018

    The healthcare industry is watching the Trump presidency closely. President Trump's promise to repeal and replace Obamacare hit repeated stumbling blocks in Congress. Despite the uncertainty surrounding these efforts to overhaul the nation's healthcare system, a number of healthcare stocks rose dramatically throughout 2017.

  • GlobeNewswirelast month

    MERGER ALERT – IVTY and EGL: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies

    NEW YORK, Sept. 14, 2018-- The following statement is being issued by Levi & Korsinsky, LLP:. Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following ...

  • Zimmer Biomet Holdings Announces Its Third-Quarter Dividend
    Market Realistlast month

    Zimmer Biomet Holdings Announces Its Third-Quarter Dividend

    Today, Zimmer Biomet Holdings (ZBH) is trading at $128.82, which represents a ~2.08% rise from yesterday’s close of $126.19.